Clinical Trials Logo

Endometrial Hyperplasia clinical trials

View clinical trials related to Endometrial Hyperplasia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06115577 Completed - Endometrial Cancer Clinical Trials

Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes

Start date: October 1, 2012
Phase:
Study type: Observational

A prospective observational study of endometrial tissue and peripheral blood mononuclear cells receptivity to sex steroid hormones in postmenopausal patients with endometrial proliferative processes

NCT ID: NCT05378152 Completed - Endometrial Cancer Clinical Trials

Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity

Start date: September 24, 2022
Phase: N/A
Study type: Interventional

Postmenopausal bleeding (PMB) is the occurrence of vaginal bleeding 12 months following a woman's last menstrual cycle. PMB represents one of the most common reasons for referral to gynaecology services. Approximately 10% of women with PMB will be found to have endometrial cancer. The gold standard of investigation of PMB is ambulatory gynaecology through the outpatient hysteroscopy clinic, which is often combined with Pipelle biopsy for endometrial sampling. Up to 60% of women that present with PMB will have an atrophic-appearing cavity at hysteroscopy. This provides a challenge in obtaining a histological sample through both dilatation & curretage (D&C) and Pipelle biopsy. Often, scant tissue that is insufficient for clinical diagnosis is obtained. Pipelle biopsy is associated with patient discomfort. It is also associated with costs related to the purchasing of equipment and the processing of samples in the laboratory to the sum of approximately 30 euro per sample. It is rare that a sample taken from an atrophic cavity will return any clinically meaningful result. A negative hysteroscopy reduces the probability of endometrial cancer to 0.6%. This study aims to compare patients with PMB and atrophic-appearing cavity that undergo pipelle biopsy to those that do not. Differences in pain scores, cost saving and differences in clinical follow up will be assessed to evaluate the benefit of Pipelle biopsy in patients with PMB and atrophic-appearing cavity.

NCT ID: NCT04873206 Completed - Clinical trials for Endometrial Adenocarcinoma

Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies

Start date: January 1, 2020
Phase:
Study type: Observational

endometrial hyperplasia may progress to endometrial adenocarcinoma. the exact possibility of such progression is not determined. there a need to detect biological markers that can help in detecting high risk cases of patients with endometrial hyperplasia that may progress to endometrial adenocarcinoma. PTEN is a tumor suppressor gene that inhibit cell migration, proliferation and may induce apoptosis in damaged cells. variable expression of PTEN in functional, hyperplastic and neoplastic endometrial tissues may be of great help in detecting cases of hyperplasia that may progress to endometrial adenocarcinoma.

NCT ID: NCT04491682 Completed - Clinical trials for Atypical Endometrial Hyperplasia

Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia

Start date: September 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

To see if megestrol acetate plus rosuvastatin will be superior to reversing the endometrial lesion to a normal endometrium than megestrol acetate alone in patients with atypical endometrial hyperplasia (AEH). Considering the large sample size in RCT, we used Simon two-stage design.

NCT ID: NCT04385667 Completed - Clinical trials for Atypical Endometrial Hyperplasia

LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia

Start date: May 20, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized controlled trial is aimed to compare the efficacy between Megestrol acetate (MA) and the levonorgestrel intrauterine system (LNG-IUD) regarding the ability and duration to produce complete regression for cases with atypical endometrial hyperplasia.

NCT ID: NCT03992937 Completed - Clinical trials for Endometrial Hyperplasia Without Atypia

Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia

Start date: June 20, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy of the vaginal micronized progesterone and Levonorgestrel-releasing Intrauterine System for treatment of non-atypical endometrial hyperplasia in premenopausal women.

NCT ID: NCT03972917 Completed - Dysmenorrhea Clinical Trials

Observation of Long-term Effects on Endometrium and Uterine Fibroids in Women With Ulipristal Acetate Therapy

Start date: November 1, 2018
Phase:
Study type: Observational

A prospective observational study on italian women undergoing ulipristal acetate (uPa) therapy for symptomatic myomas and its impact on symptomatology and moreover on myomas architecture. We also evaluate changes in the endometrial pattern of selected women.

NCT ID: NCT03965585 Completed - Infertility, Female Clinical Trials

Office Hysteroscopy in Infertility Work-out: the Role of Endometrial Hyperplasia in Southern Italian Women

Start date: January 2, 2019
Phase:
Study type: Observational

To assess the prevalence of endometrial hyperplasia (EH), endometrial intraepithelial neoplasia (EIN) and endometrial carcinoma between obese and not obese women undergoing IVF techniques for primary or secondary infertility.

NCT ID: NCT03917147 Completed - Clinical trials for Endometrial Neoplasms

Correlation Between Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination

Start date: January 8, 2018
Phase:
Study type: Observational

A prospective cohort study at a Tertiary University Hospital. From January to December 2018, we enrolled women with the following criteria: abnormal uterine bleeding in post-menopause, endometrial thickening in pre-or post-menopause; tamoxifen usage. Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Senior operators had to foresee histopathological diagnosis using a questionnaire. Histopathological examination was conducted to confirm the diagnosis.

NCT ID: NCT03675139 Completed - Clinical trials for Endometrial Hyperplasia Without Atypia

MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

Start date: February 26, 2019
Phase: Phase 3
Study type: Interventional

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.